 MONMOUTH JUNCTION, N.J., Aug. 12, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Company has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration FDA. 